178 related articles for article (PubMed ID: 23759037)
21. Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion.
Loncar R; Ostojic L; Tabakovic-Loncar V; Roguljić A
Tumori; 1995; 81(6):440-4. PubMed ID: 8804473
[TBL] [Abstract][Full Text] [Related]
22. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions.
Korczyński P; Mierzejewski M; Krenke R; Safianowska A; Light RW
Pol Arch Intern Med; 2018 Jun; 128(6):354-361. PubMed ID: 29968696
[TBL] [Abstract][Full Text] [Related]
23. Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience.
Porcel JM; Civit C; Esquerda A; Salud A; Bielsa S
Arch Bronconeumol; 2017 Aug; 53(8):427-431. PubMed ID: 28237067
[TBL] [Abstract][Full Text] [Related]
24. Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions.
Wang T; Qian X; Wang Z; Wang L; Yu L; Ding Y; Liu B
Int J Cancer; 2009 Oct; 125(8):1921-5. PubMed ID: 19585499
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and predictive role of cell-free midkine in malignant pleural effusions.
Lv M; Mou Y; Wang P; Chen Y; Wang T; Hou Y
J Cancer Res Clin Oncol; 2013 Apr; 139(4):543-9. PubMed ID: 23212314
[TBL] [Abstract][Full Text] [Related]
26. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer.
Iwao K; Watanabe T; Fujiwara Y; Takami K; Kodama K; Higashiyama M; Yokouchi H; Ozaki K; Monden M; Tanigami A
Int J Cancer; 2001 Feb; 91(4):433-7. PubMed ID: 11251963
[TBL] [Abstract][Full Text] [Related]
27. How should cancer presenting as a malignant pleural effusion be managed?
Bonnefoi H; Smith IE
Br J Cancer; 1996 Sep; 74(5):832-5. PubMed ID: 8795590
[TBL] [Abstract][Full Text] [Related]
28. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies.
Hackbarth JS; Murata K; Reilly WM; Algeciras-Schimnich A
Clin Biochem; 2010 Sep; 43(13-14):1051-5. PubMed ID: 20529669
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.
Han HS; Yun J; Lim SN; Han JH; Lee KH; Kim ST; Kang MH; Son SM; Lee YM; Choi SY; Yun SJ; Kim WJ; Lee OJ
Int J Cancer; 2013 Aug; 133(3):645-52. PubMed ID: 23354517
[TBL] [Abstract][Full Text] [Related]
30. Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study.
Ma Z; Li H; Wang B; Shen Q; Cui E; Min L; Qian F; Ping J; Dai L
J Cancer Res Clin Oncol; 2013 Apr; 139(4):557-62. PubMed ID: 23224432
[TBL] [Abstract][Full Text] [Related]
31. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
34. Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world.
Pan P; Wu F; Xu Z; Ji X; Qi Q; Huang X; Zhao R; Liu M; Jiang P; Li Y; Xu L
Thorac Cancer; 2021 Dec; 12(24):3416-3425. PubMed ID: 34741494
[TBL] [Abstract][Full Text] [Related]
35. Expression and clinical significance of lung-specific X protein mRNA in bronchial brushing specimens from patients with or without lung cancer.
Lv M; Wu MZ; Zhao YJ; Yang DI; Wang EH; Wu GP
Respirology; 2011 Oct; 16(7):1076-80. PubMed ID: 21651644
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
37. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis.
Cheng C; Yang Y; Yang W; Wang D; Yao C
Expert Rev Respir Med; 2022 Jan; 16(1):99-108. PubMed ID: 34112035
[TBL] [Abstract][Full Text] [Related]
39. Sestrin-2 is significantly increased in malignant pleural effusions due to lung cancer and is potentially secreted by pleural mesothelial cells.
Tsilioni I; Filippidis AS; Kerenidi T; Budanov AV; Zarogiannis SG; Gourgoulianis KI
Clin Biochem; 2016 Jun; 49(9):726-728. PubMed ID: 26874199
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of interleukin 21 and carcinoembryonic antigen levels in malignant pleural effusions.
Bunjhoo H; Wang ZY; Chen HL; Cheng S; Xiong WN; Xu YJ; Cao Y
Asian Pac J Cancer Prev; 2012; 13(7):3495-9. PubMed ID: 22994784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
